Edition:
United Kingdom

People: Mithra Pharmaceuticals SA (MITRA.BR)

MITRA.BR on Brussels Stock Exchange

27.10EUR
19 Jul 2019
Change (% chg)

€0.04 (+0.15%)
Prev Close
€27.06
Open
€27.10
Day's High
€27.46
Day's Low
€26.80
Volume
40,867
Avg. Vol
34,847
52-wk High
€37.50
52-wk Low
€18.12

Gordenne, Valerie 

Ms. Valerie Gordenne is Chief Scientific Officer - Representing ALIUS MODI SPRL of the Company. Ms Gordenne has over 18 years of experience in the pharma industry with strong focus on R&D, (non)clinical trials, regulatory affairs and manufacturing. She holds a Master Degree in Pharmaceutical Sciences (Industrial Pharmacist) from the University of Liège. She started her career in Research and Development for a medium size pharmaceutical company called SMB Technology as Project Manager, and later become Qualified Person for a manufacturing site dedicated to investigational medicinal products. In 2004 she joined Mithra as Qualified Person where responsibilities also included Regulatory Affairs for pre- and post-marketing portfolio. Between 2008 and 2012 she acted as General Manager of Odyssea Pharma SA, the site dedicated to hormonal intra-uterine system Levosert© which is now a subsidiary of Actavis (NYSE: ACT). Following the acquisition of Uteron Pharma by Watson/Actavis (NYSE: ACT), she returned to Mithra as Chief Scientific Officer. Responsibilities at Mithra include R&D for the Company’s portfolio from discovery to marketing authorization

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --